BOARD OF DIRECTORS
Khalid Islam, PhD
Dr. Islam has over 30 years of Pharma and Biotech industry experience. He is currently the Chairman of the Board of Directors of Fennec Pharmaceuticals,and Minoryx Therapeutics S.L. and a member of the Board of Directors of Immunomedics Inc. He has been the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where, under his leadership Defitelio was granted Marketing Authorisation and the company value increased from 25m USD leading to all cash 1billion USD merger with Jazz Pharmaceuticals, plc. From 1999-2008, he was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised 300m USD in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). Previously, he has been a member of the Board of Directors of Karolinska Development, Molmed, OxThera, Arpida AG , Rheoscience AS; PCovery AS, Adenium AS and C10 Pharma AS. He is also as an advisor to Kurma Biofund (Paris).
Lorenzo Leoni, PhD
Dr. Leoni has more than 20 years of drug development experience. He is currently Managing Partner of TiVenture. He is a scientific serial entrepreneur and founder of several biomedical companies in the US and in Europe (Salmedix Inc, Telormedix SA, Elion Oncology Inc, Oculox Technologies SA, BioPharmaTi Ltd). He holds Board positions in several technology companies and has an extensive network at the academic, financial and industrial level in Biotech and MedTech.
Dr. Leoni was an Assistant Professor at the Department of Medicine at UCSD in San Diego, working in the fields of oncology and immunology. He holds a Ph.D. in Biochemistry from the University of Lausanne
Eric I. Richman
Member & CEO
Mr. Richman has over 25 years of experience in the biotechnology and pharmaceutical industry as an investor and in operating roles. He previously served as a Venture Partner at Brace Pharma Capital, a life science venture capital firm and served as Chief Executive Officer of Tyrogenex Inc., a biopharmaceutical company and Chief Executive Officer of PharmAthene, Inc. subsequently acquired by Altimmune, Inc. He previously held various commercial and strategic positions at MedImmune, Inc. over a 12-year period from its inception. Mr. Richman currently serves as a director of Neubase Therapeutics, Inc. (Nasdaq: NBSE), NovelStem International Corp. (OTCMKTS: NSTM), and co-founder and director of InFuse Holdings and LabConnect, Inc. where he serves as the Chairman of the Board. He previously served on a number of Boards including Adma Biologics, Inc. (Nasdaq: ADMA), Zyversa Therapeutics, Inc., LEV Pharma (OTC: LEVP) (acq. by Viropharma), among others. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a M.B.A. from the American Graduate School of International Management.
Marianne Bjordal, PhD
Dr. Bjordal is a Senior Associate at the Helsinn Investment Fund. She is an experienced scientist with over 15 years of research expertise focusing on metabolism, nutrient sensing and neuroendocrine signaling. Marianne holds a Masters Degree in Molecular Biology from the University of Bergen, Norway and a Ph.D. in Molecular and Cellular Biology as well as an MBA from the University of Nice, France. She is a former Marie Curie Early Stage Researcher and former researcher at the CNRS. In 2014 she received the AXA Prize from the French Academy of Science.
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in their capacity of business development and general management. He has served on public and private Boards in the USA and Australia. He has a BS degree (Boise State University), a MBA/MIM (Thunderbird/Arizona State) and advanced science work (UC San Francisco/Berkeley)